NasdaqGM:XOMA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

XOMA Corporation, a biotech royalty aggregator, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. More Details


Snowflake Analysis

High growth potential with excellent balance sheet.

Share Price & News

How has XOMA's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: XOMA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

18.2%

XOMA

-1.2%

US Biotechs

-1.1%

US Market


1 Year Return

20.4%

XOMA

30.7%

US Biotechs

15.6%

US Market

Return vs Industry: XOMA underperformed the US Biotechs industry which returned 32.5% over the past year.

Return vs Market: XOMA matched the US Market which returned 17.8% over the past year.


Shareholder returns

XOMAIndustryMarket
7 Day18.2%-1.2%-1.1%
30 Day24.5%1.3%4.2%
90 Day38.9%-2.5%6.3%
1 Year20.4%20.4%33.0%30.7%18.2%15.6%
3 Year-3.3%-3.3%19.6%13.6%39.6%30.4%
5 Year-36.5%-36.5%8.7%1.0%79.5%59.2%

Price Volatility Vs. Market

How volatile is XOMA's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is XOMA undervalued compared to its fair value and its price relative to the market?

6.74x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate XOMA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate XOMA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: XOMA is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: XOMA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate XOMA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: XOMA is overvalued based on its PB Ratio (6.5x) compared to the US Biotechs industry average (3.4x).


Next Steps

Future Growth

How is XOMA forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

77.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: XOMA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: XOMA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: XOMA's is expected to become profitable in the next 3 years.

Revenue vs Market: XOMA's revenue (37.8% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: XOMA's revenue (37.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if XOMA's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has XOMA performed over the past 5 years?

40.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: XOMA is currently unprofitable.

Growing Profit Margin: XOMA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: XOMA is unprofitable, but has reduced losses over the past 5 years at a rate of 40.7% per year.

Accelerating Growth: Unable to compare XOMA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XOMA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.1%).


Return on Equity

High ROE: XOMA has a negative Return on Equity (-24.57%), as it is currently unprofitable.


Next Steps

Financial Health

How is XOMA's financial position?


Financial Position Analysis

Short Term Liabilities: XOMA's short term assets ($52.3M) exceed its short term liabilities ($11.3M).

Long Term Liabilities: XOMA's short term assets ($52.3M) exceed its long term liabilities ($38.2M).


Debt to Equity History and Analysis

Debt Level: XOMA's debt to equity ratio (81%) is considered high.

Reducing Debt: XOMA had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: XOMA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: XOMA has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 29.4% each year


Next Steps

Dividend

What is XOMA current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate XOMA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate XOMA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if XOMA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if XOMA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of XOMA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure


CEO

Jim Neal (64 yo)

3.83yrs

Tenure

US$1,479,559

Compensation

Mr. James R. Neal, also known as Jim, serves as Director at Leading BioSciences Inc since October 30, 2018. He has been the Chief Executive Officer at XOMA Corporation since December 21, 2016 and served as ...


CEO Compensation Analysis

Compensation vs Market: Jim's total compensation ($USD1.48M) is about average for companies of similar size in the US market ($USD1.23M).

Compensation vs Earnings: Jim's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
James Neal
CEO & Director3.83yrsUS$1.48m0.19%
$ 489.5k
Thomas Burns
Senior VP of Finance & CFO5.5yrsUS$813.21k0.059%
$ 153.9k
Danny Hart
VP & General Counsel2.75yrsno datano data

3.8yrs

Average Tenure

46yo

Average Age

Experienced Management: XOMA's management team is considered experienced (3.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
James Neal
CEO & Director3.83yrsUS$1.48m0.19%
$ 489.5k
Jack Wyszomierski
Independent Director10.17yrsUS$166.99k0.059%
$ 151.8k
Joseph Limber
Independent Director7.83yrsUS$159.99k0.056%
$ 145.8k
W. Van Ness
Chairman of the Board & Lead Independent Director9.17yrsUS$200.99k0.090%
$ 233.5k
Matthew Perry
Independent Director3.67yrsUS$145.99k0.11%
$ 277.0k
Barbara Kosacz
Independent Director1.75yrsUS$350.39k0%
$ 0
Natasha Hernday
Director0.25yrno datano data

3.8yrs

Average Tenure

64yo

Average Age

Experienced Board: XOMA's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 26.2%.


Top Shareholders

Company Information

XOMA Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: XOMA Corporation
  • Ticker: XOMA
  • Exchange: NasdaqGM
  • Founded: 1981
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$258.706m
  • Shares outstanding: 11.02m
  • Website: https://www.xoma.com

Number of Employees


Location

  • XOMA Corporation
  • 2200 Powell Street
  • Suite 310
  • EmeryVille
  • California
  • 94608
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
XOMANasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJun 1986
X0M1DB (Deutsche Boerse AG)YesCommon StockDEEURJun 1986
0M26LSE (London Stock Exchange)YesCommon StockGBUSDJun 1986

Biography

XOMA Corporation, a biotech royalty aggregator, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and tec ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/27 00:22
End of Day Share Price2020/10/26 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.